Suven Life Sciences, a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, has received a product patent in Australia and Mexico for one of its new chemical entity (NCE) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2022 and 2025.
With these new patents, Suven has a total of eight granted product patents for their NCEs in CNS therapy both in Australia and Mexico. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizopherenia.
Venkat Jasti, CEO of Suven, said, "WE are very pleased by the grant of these patents to Suven by the patent offices of Australia and Mexico for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $30 billion market potential globally".
Currently, Suven has 12 internally discovered therapeutic drug candidates in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, huntington's disease, parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.